Skip to main content
. Author manuscript; available in PMC: 2017 Jul 4.
Published in final edited form as: Sci Transl Med. 2017 Jan 4;9(371):eaaf8611. doi: 10.1126/scitranslmed.aaf8611

Fig. 1. Participant characteristics.

Fig. 1

(A) Flow diagram of subjects that were assessed and analyzed for the primary outcome of ClinicalTrials.gov NCT01327937. (B). Subject demographics; ulcer size at screening was determined at time of enrollment (study week –4), whereas size at allocation was determined at week 0, when patients were randomly assigned to BLCC or control treatment groups. Asterisk (*) indicates the sample biomaterial was of insufficient quality for sensitive microarray analysis but was available for validation of study findings.